KAZIA THERAPEUTICS LTD (KZIA) Form 424B3 — Aug 27, 2026
Kazia Therapeutics announced that its lead asset paxalisib achieved a 100% clinical benefit rate in six evaluable patients with Stage IV triple-negative breast cancer, with five of six achieving an objective response (one complete, four partial) for an 83% response rate, and no paxalisib-related serious adverse events observed. Translational analyses showed median reductions of 83% in circulating tumor cell clusters and 51% in terminally exhausted CD8+ T cells across all six patients, and one 44-year-old patient has maintained a complete metabolic response with no evidence of disease since November 2025.
Key figures
- Cash Position
- approximately US$46 million as of 12/31/25
- Shares Offered
- 10700211
- Cash Runway
- expected to fund planned operations into 2029 (excluding additional or expanded trials)
- Outstanding Debt
- 0
- Last Sale Price Date
- 2026-08-26
- Total SAEs Reported
- 13
- Clinical Benefit Rate
- 100% (6/6 evaluable Stage IV TNBC patients)
- Paxalisib Related SAEs
- 0
- Objective Response Rate
- 83% (5/6 patients: 1 complete response, 4 partial responses)
- Addressable Market Claim
- >$40B (TNBC ~$6B by 2030, HR+/HER2- breast cancer ~$17B by 2030, pMMR CRC ~$18B by 2030)
- Median CTCCluster Reduction
- 83% (range 76-90%) within 6-7 weeks
- Ordinary Shares Represented
- 5350105500
- Ads Outstanding Fully Diluted
- approximately 14.1 million
- Last Reported Sale Price Per ADS
- 14.6
- Median Exhausted TCell Reduction
- 51% (range 18-97%) within ~3 weeks
- Patients Dosed With Paxalisib To Date
- >550 across Phase 1-3 trials and expanded access programs
- Phase1b Enrollment Completion Expected
- July 2027
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.